FDA Approves First Drug Doubling Pancreatic Cancer Survival

A once-daily pill just became the biggest breakthrough in pancreatic cancer treatment history, offering new hope for a disease with a five-year survival rate of just 13%.

The FDA has approved RASONQUE (daraxonrasib), a targeted therapy that attacks the genetic mutations driving more than 90% of pancreatic cancer cases. The drug doubled survival time in clinical trials, with patients living a median of 13.2 months compared to 6.7 months on standard chemotherapy.

"This is the most significant advancement we have ever seen in the fight against pancreatic cancer," said Dr. Anna Berkenblit, Chief Scientific Officer at the Pancreatic Cancer Action Network. The approval marks what she calls "the beginning of a new era" for treating this devastating disease.

RASONQUE is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior treatment or cannot tolerate standard chemotherapy. This means it's available both as a second-line treatment and for some newly diagnosed patients.

The drug works by blocking RAS proteins, which regulate cell growth. Mutations in these proteins, particularly in the KRAS gene, essentially flip an "on" switch for constant cell growth, fueling tumor formation. For decades, scientists called these mutations "undruggable" because they seemed impossible to target.

Clinical trial participants who received RASONQUE didn't just live longer. They also reported better quality of life and improved pain control compared to those on chemotherapy, giving patients not just more time but better time with their families.

The Ripple Effect

This approval represents more than one new treatment option. It proves that previously "impossible" targets can be conquered, opening the door for even more advances in cancer treatment. The success of RASONQUE shows researchers worldwide that persistent innovation pays off, potentially accelerating development of similar therapies for other cancers driven by these mutations.

The drug was previously available only through clinical trials and a limited Expanded Access Program. Now oncologists can prescribe it to eligible patients, with insurance coverage available.

The most common side effects include rash (affecting 86% of patients), mouth sores, and diarrhea. About 14% of rash cases were considered severe, though the condition was manageable for most patients.

Patients interested in RASONQUE should talk with their healthcare team about whether it's right for their situation. The Pancreatic Cancer Action Network offers free one-on-one support to help patients prepare for informed conversations with their doctors.

While RASONQUE was approved regardless of mutation status, experts still recommend biomarker testing for all pancreatic cancer patients to identify the specific changes in their tumors and explore all available treatment options.

After decades of limited progress against one of cancer's deadliest forms, patients and families finally have reason for renewed hope.